Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

48.00USD
25 Mar 2019
Change (% chg)

$-0.16 (-0.33%)
Prev Close
$48.16
Open
$48.15
Day's High
$48.20
Day's Low
$47.96
Volume
182,533
Avg. Vol
4,305,773
52-wk High
$63.75
52-wk Low
$44.30

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $78,629.67
Shares Outstanding(Mil.): 1,632.68
Dividend: 0.41
Yield (%): 3.41

Financials

  BMY.N Industry Sector
P/E (TTM): 15.85 57.67 58.10
EPS (TTM): 3.04 -- --
ROI: 20.79 12.55 12.12
ROE: 38.62 13.54 13.24

U.S. FDA approves Roche's small cell lung cancer treatment

March 18 Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

Mar 18 2019

Third Point holds Celgene stock, in bet Bristol-Myers deal will close: source

Daniel Loeb's hedge fund Third Point LLC owns a small stake in Celgene Corp, betting that the proposed $74 billion sale of the biotechnology company to Bristol-Myers Squibb Co will be completed, a person familiar with the matter said on Monday.

Mar 11 2019

Third Point holds Celgene stock, in bet Bristol-Myers deal will close -source

March 11 Daniel Loeb's hedge fund Third Point LLC owns a small stake in Celgene Corp, betting that the proposed $74 billion sale of the biotechnology company to Bristol-Myers Squibb Co will be completed, a person familiar with the matter said on Monday.

Mar 11 2019

UPDATE 2-Roche's Tecentriq notches win in breast cancer with U.S. approval

* Roche trails Bristol, Merck in immunotherapy sales (Adds comment from doctor about approval)

Mar 08 2019

Starboard builds stake in Zayo, presses for sale

Activist hedge fund Starboard Value LP has amassed a 4 percent stake in Zayo Group Holdings Inc and is asking the U.S. communications infrastructure provider to consider a sale, according to a letter sent by Starboard to Zayo on Thursday.

Mar 07 2019

UPDATE 2-Starboard builds stake in Zayo, presses for sale

March 7 Activist hedge fund Starboard Value LP has amassed a 4 percent stake in Zayo Group Holdings Inc and is asking the U.S. communications infrastructure provider to consider a sale, according to a letter sent by Starboard to Zayo on Thursday.

Mar 07 2019

Starboard builds stake in Zayo, presses for sale

March 7 Activist hedge fund Starboard Value LP has amassed a 4 percent stake in Zayo Group Holdings Inc and is asking the U.S. communications infrastructure provider to consider a sale, according to a letter sent by Starboard to Zayo on Thursday.

Mar 07 2019

Bristol-Myers defends Celgene bet as investor criticism grows

Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a "robust" assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.

Mar 06 2019

UPDATE 4-Bristol-Myers defends Celgene bet as investor criticism grows

March 6 Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a "robust" assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.

Mar 06 2019

Celgene buy best path forward, Bristol-Myers says

March 6 Bristol-Myers Squibb's planned $74 billion takeover of Celgene Corp is the best path forward for value creation, the company said in an investor presentation on Wednesday.

Mar 06 2019

Earnings vs. Estimates